Effect of bempedoic acid on new onset or worsening diabetes: A meta-analysis. Masson, W.; Lobo, M.; Lavalle-Cobo, A.; Masson, G.; and Molinero, G. Diabetes Research and Clinical Practice, Elsevier Ireland Ltd, 10, 2020.
Effect of bempedoic acid on new onset or worsening diabetes: A meta-analysis [link]Website  abstract   bibtex   
Introduction: Bempedoic acid is a new agent that reduces low-density lipoprotein cholesterol. Since inhibits cholesterol synthesis through a different mechanism than statins, the adverse effects related to it may also be different. Therefore, the objective of the present meta-analysis was to evaluate the effect of bempedoic acid on new onset or worsening diabetes. Methods: We performed a meta-analysis including randomized trials of bempedoic acid therapy, reporting new onset or worsening diabetes with a minimum of 4 weeks of follow-up. The fixed-effects model was performed. This meta-analysis was performed according to PRISMA guidelines. Results: Five eligible trials of bempedoic acid, including 3629 patients, were identified and considered eligible for the analyses. A total of 2419 subjects were allocated to receive bempedoic acid while 1210 subjects were allocated to the respective control arms. Bempedoic acid therapy is associated with a significant reduction in new onset or worsening diabetes [Odds Ratio: 0.66, 95% confidence interval: 0.48–0.90; I2: 0%]. Conclusion: This data suggests that the use of bempedoic acid significantly reduces the new onset or worsening diabetes risk. This finding should be confirmed with future studies.
@article{
 title = {Effect of bempedoic acid on new onset or worsening diabetes: A meta-analysis},
 type = {article},
 year = {2020},
 identifiers = {[object Object]},
 keywords = {Bempedoic acid,Meta-analysis,New onset diabetes,Worsernig diabetes},
 volume = {168},
 websites = {http://www.diabetesresearchclinicalpractice.com/article/S0168822720306227/fulltext,http://www.diabetesresearchclinicalpractice.com/article/S0168822720306227/abstract,https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(20)30622-7/abstract},
 month = {10},
 publisher = {Elsevier Ireland Ltd},
 day = {1},
 id = {e00167f2-9ea1-3c01-9db8-96aa1faa8650},
 created = {2020-10-09T14:36:46.407Z},
 accessed = {2020-10-09},
 file_attached = {false},
 profile_id = {3bb26c79-1cd6-3945-ac65-a972949fa8b1},
 group_id = {2f9515a1-f4bb-3e7d-9747-925ba4576996},
 last_modified = {2020-10-09T14:36:46.407Z},
 read = {false},
 starred = {false},
 authored = {false},
 confirmed = {false},
 hidden = {false},
 private_publication = {false},
 abstract = {Introduction: Bempedoic acid is a new agent that reduces low-density lipoprotein cholesterol. Since inhibits cholesterol synthesis through a different mechanism than statins, the adverse effects related to it may also be different. Therefore, the objective of the present meta-analysis was to evaluate the effect of bempedoic acid on new onset or worsening diabetes. Methods: We performed a meta-analysis including randomized trials of bempedoic acid therapy, reporting new onset or worsening diabetes with a minimum of 4 weeks of follow-up. The fixed-effects model was performed. This meta-analysis was performed according to PRISMA guidelines. Results: Five eligible trials of bempedoic acid, including 3629 patients, were identified and considered eligible for the analyses. A total of 2419 subjects were allocated to receive bempedoic acid while 1210 subjects were allocated to the respective control arms. Bempedoic acid therapy is associated with a significant reduction in new onset or worsening diabetes [Odds Ratio: 0.66, 95% confidence interval: 0.48–0.90; I2: 0%]. Conclusion: This data suggests that the use of bempedoic acid significantly reduces the new onset or worsening diabetes risk. This finding should be confirmed with future studies.},
 bibtype = {article},
 author = {Masson, Walter and Lobo, Martín and Lavalle-Cobo, Augusto and Masson, Gerardo and Molinero, Graciela},
 journal = {Diabetes Research and Clinical Practice}
}
Downloads: 0